Sanofi unveils mixed news for Zaltrap cancer drug

PARIS Thu Apr 5, 2012 11:23am IST

Related Topics

Stocks

   

PARIS (Reuters) - Sanofi and Regeneron Pharmaceuticals said their Zaltrap drug candidate failed to meet targets in a late-stage study for the treatment of prostate cancer, though U.S. authorities were reviewing it for use in treating colon cancer.

Regeneron had said in December that Sanofi had withdrawn its application for marketing approval for Zaltrap and was planning to resubmit it early this year.

"The study did not meet the pre-specified criterion of improvement in overall survival," Sanofi said, referring to a Phase III study of Zaltrap, also known as aflibercept, in treating prostate cancer.

Sanofi added in a statement on Thursday that the U.S. Food and Drug Administration had granted a priority review to the companies to examine Zaltrap in the treatment of colon cancer. The FDA is due to give a decision by August 4.

Priority review is granted to a drug if preliminary estimates show it has the potential to provide a treatment where no adequate therapy exists or a significant improvement compared with marketed products, Sanofi said.

"Sanofi and Regeneron are committed to the continued development of Zaltrap," Sanofi oncology head Debasish Roychowdhury said in the statement.

(Reporting by Nina Sovich; Editing by James Regan)

FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.

  • Most Popular
  • Most Shared

Ebola outbreak

REUTERS SHOWCASE

Reading the Brain

Reading the Brain

Guilt may spoil restorative effects of entertainment.  Full Article 

Heart Matters

Heart Matters

Weekday heart attacks still getting quicker treatment at hospitals.  Full Article 

Tackling Stress

Tackling Stress

'Interreality' may enhance stress therapies.  Full Article 

Jogging Helps

Jogging Helps

Short jogs linked to lower risk of death from heart disease.  Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device.  Full Coverage